zepbound glp-1 receptor agonist hydration effects 2025 GI Adverse of Glucagon-Like Peptide-1 Agonists GLP-1 for Prevention: Using Drugs

doi: 10.2967/jnumed.106.038679 [DOI] [PubMed] [Google Scholar] 80.Oh YS, Jun HS

112 However, in recent years, the FDA has introduced the patient-focused drug development initiative, where patient-reported outcomes such as improvements in quality of life and healthy life years in MASH patients following treatment can serve as trial endpoints, potentially influencing final approval based on these data

Results in trial reports (primary trial results and subsequent secondary publications), and their accompanying Additional file 1, were used as the primary source of information

FTI Consultings survey shows that more than 20 percent of US adults have used them in the past 12 months, despite high costs, side effects and the need for injectable delivery

Optum Rx can provide precision analytics to demonstrate cost impacts spanning multiple scenarios as well as expert clinical consultation and insights to help you make timely decisions